RecruitingAlzheimer Disease
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Eligible age
50–85 yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Sponsor: InSightec
You may qualify if…
- ✓ 1. Male or Female between 50-85 years of age
- ✓ 2. Probable Alzheimer's Disease (AD)
- ✓ 3. If taking concurrent Alzheimer's medication, has been on the medication for at least 2 months with a stable dose for at least 3 months
- ✓ 4. Able to communicate sensations during the ExAblate MRgFUS procedure
- ✓ 5. Ambulatory
You may not qualify if…
- ✕ 1. MRI Findings
- ✕ 2. Presence of unknown or MR unsafe devices anywhere in the body
- ✕ 3. Significant cardiac disease or unstable hemodynamic status
- ✕ 4. Relative contraindications to ultrasound contrast agent or PET amyloid tracer
- ✕ 5. History of a bleeding disorder
- ✕ 6. History of liver disease
- ✕ 7. Known cerebral or systemic vasculopathy
- ✕ 8. Significant depression and at potential risk of suicide
Where it's recruiting
Florida
Delray Beach · Fort Lauderdale · Gainesville · Miami …
New York
New York
Ohio
Columbus
Texas
Dallas
West Virginia
Morgantown
Source: ClinicalTrials.gov · NCT03671889 · last updated 2026-01-09